Search

Your search keyword '"Term (time)"' showing total 204 results
Start Over "Term (time)" Topic medicine.disease Journal value in health
204 results on '"Term (time)"'

1. PSS16 Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers' Compensation for Employees with Osteoarthritis in the United States

Author

I.A. Beren, Richard A. Brook, and Nathan L. Kleinman

Subjects
business.industry, Health Policy, media_common.quotation_subject, Rheumatoid arthritis, Public Health, Environmental and Occupational Health, Medicine, Workers' compensation, Demographic economics, Payment, business, medicine.disease, media_common, Term (time)
Published
2021

2. PCV2 Real-World Outcomes of Antithrombotic Therapies in Patients with Coronary Artery Disease That Require Long-Term Oral Anticoagulation

Author

A. Osterland, R.J. Widmer, and P.J. Godley

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Real world outcomes, medicine.disease, Term (time), Coronary artery disease, Antithrombotic, medicine, In patient, Intensive care medicine, business, Oral anticoagulation
Published
2021

3. PND9 Exploring Serious Adverse Events Associated With Hospitalizations in a Long-term, Phase 3, Open-Label, Repeat-Dose, Safety Study of Diazepam Nasal Spray for Patients With Epilepsy

Author

M. Sperling, R.E. Hogan, A.L. Rabinowicz, James W. Wheless, D. Tarquinio, E. Carrazana, N. Fountain, and Dennis J. Dlugos

Subjects
business.industry, Health Policy, medicine.medical_treatment, Public Health, Environmental and Occupational Health, medicine.disease, Repeat dose, Term (time), Epilepsy, Nasal spray, Anesthesia, medicine, Open label, business, Adverse effect, Diazepam, medicine.drug
Published
2021

5. PCV27 COST-EFFECTIVENESS OF INSERTABLE CARDIAC MONITORS VERSUS STANDARD OF CARE OR SHORT-TO-LONG-TERM ECG MONITORING TO IDENTIFY ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE

Author

Matthew R. Reynolds, Sarah C Rosemas, K K Witte, L. Sawyer, Shadi Yaghi, F. Grimsey Jones, Paul D. Ziegler, Rachelle E Kaplon, and Suneet Mittal

Subjects
medicine.medical_specialty, Standard of care, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Atrial fibrillation, medicine.disease, Term (time), Cryptogenic stroke, Ecg monitoring, Internal medicine, medicine, Cardiology, Cardiac monitors, business
Published
2020

7. CE1 METHODOLOGICAL CHALLENGES WITH CONDUCTING NETWORK META-ANALYSES ASSESSING LONG-TERM COMPARATIVE EFFICACY IN PSORIASIS: A CRITIQUE OF ASSUMPTIONS UNDERPINNING RECENT INDIRECT TREATMENT COMPARISONS

Author

J.P. Jansen, K. Eaton, Sandhya Nair, Chris Cameron, Timothy Disher, S. Peterson, R. Villacorta, and Brian Hutton

Subjects
Underpinning, Psychotherapist, Network Meta-Analyses, Indirect Treatment, Health Policy, Psoriasis, Public Health, Environmental and Occupational Health, medicine, Psychology, medicine.disease, Term (time)
Published
2020

8. PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM)

Author

D. Moldaver, M. Afonso, J. Bartelt-Hofer, Daniel T. Grima, M. Ainslie-Garcia, and L. Sauriol

Subjects
Type 1 diabetes, medicine.medical_specialty, business.industry, Health Policy, Diabetes mellitus, Internal medicine, Public Health, Environmental and Occupational Health, medicine, External validation, medicine.disease, business, Term (time)
Published
2019

9. PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA

Author

M. Ghiani, Bernd Bokemeyer, David Myers, Ulf Maywald, Dominik Naessens, Thomas Wilke, and Péter Takács

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Ulcerative colitis, language.human_language, Term (time), German, Claims data, medicine, language, In patient, Intensive care medicine, business
Published
2019

11. PDB28 MODEL-Based LONG-TERM Cost-Effectiveness of Once-Weekly Semaglutide Compared with Other GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Literature Review

Author

R. Zhen, H. Shi, Hao Hu, and Ling Yang

Subjects
Oncology, medicine.medical_specialty, Cost effectiveness, business.industry, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Once weekly, Type 2 diabetes, medicine.disease, Term (time), Systematic review, Internal medicine, medicine, business, Glucagon-like peptide 1 receptor
Published
2020

12. PCN348 Long-Term Healthcare Resource Utilization and Costs Associated with Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer

Author

R. Jolivel, Anne-Françoise Gaudin, R. Corre, C.Y. Calvet, Christos Chouaid, Jean-Baptiste Assié, V. Grumberg, B. Jouaneton, François-Emery Cotté, and M. Giaj-Levra

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Term (time), Internal medicine, Health care, medicine, Non small cell, Nivolumab, business, Lung cancer, Resource utilization
Published
2020

13. PDB32 A LONG-TERM Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 MG Versus Once-Daily Empagliflozin 25 MG

Author

C. Costa, N. Hallén, B. Hunt, and D. Carvalho

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Once weekly, Type 2 diabetes, Cost-effectiveness analysis, medicine.disease, Term (time), Empagliflozin, Medicine, Once daily, business
Published
2020

14. PDB36 LONG-TERM Cost-Effectiveness Analyses of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Type 2 Diabetes in Three Countries: Bosnia and Herzegovina, Greece, and Slovenia

Author

N. Hallén, S. Liatis, A. Thanopoulou, A. Ogrič Lapajne, I. Ioannidis, D. Djekic, and B. Hunt

Subjects
Cost effectiveness, business.industry, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Empagliflozin, medicine, Once weekly, Type 2 diabetes, medicine.disease, business, Term (time), Demography
Published
2020

15. PMS32 LONG–TERM PAIN Management Pathways of Patients with Osteoarthritis of the HIP/Knee before Joint Replacement — a Retrospective Cohort Study Based on German Health Claims DATA

Author

M. Schild, W. Galetzka, U. Müller, A. Mocek, H Gothe, and T.C. Ploner

Subjects
medicine.medical_specialty, business.industry, Joint replacement, Health Policy, medicine.medical_treatment, Public Health, Environmental and Occupational Health, Retrospective cohort study, Osteoarthritis, Pain management, medicine.disease, language.human_language, Term (time), German, Health claims on food labels, language, Physical therapy, Medicine, business
Published
2020

16. PDG12 THE LONG-TERM COST-EFFECTIVENESS OF VILDAGLIPTIN+ METFORMIN THERAPY RELATIVE TO COMPARATOR SULFONYLUREA+ METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

Author

J. Xu

Subjects
Oncology, medicine.medical_specialty, business.industry, Cost effectiveness, medicine.drug_class, Health Policy, Public Health, Environmental and Occupational Health, Type 2 diabetes, medicine.disease, Sulfonylurea, Metformin, Term (time), Internal medicine, medicine, In patient, Vildagliptin, business, medicine.drug
Published
2020

17. PCN121 LONG-TERM COST-EFFECTIVENESS MODELING COMPARING MATURITY OF DATA CUTS: A COMPARISON BETWEEN COST-EFFECTIVENESS OF NIVOLUMAB VS EVEROLIMUS IN SECOND LINE RENAL CELL CARCINOMA USING 2- OR 3-YEAR FOLLOW UP CHECKMATE-025 DATA

Author

H. Sandhu and A. Berardi

Subjects
Oncology, medicine.medical_specialty, Everolimus, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Checkmate, medicine.disease, Maturity (finance), Term (time), Second line, Renal cell carcinoma, Internal medicine, medicine, Nivolumab, business, medicine.drug
Published
2020

19. PCN293 HOW SUCCESSFUL ARE STANDARD AND FLEXIBLE EXTRAPOLATION METHODS FOR THE LONG-TERM PROJECTION OF OVERALL SURVIVAL COMPARED TO TRIAL DATA SUBSEQUENTLY MADE AVAILABLE FOR CANCER IMMUNOTHERAPIES?

Author

M. Cooper, R. Aguiar-Ibáñez, T. Williams, S. Smith, and T. Harding

Subjects
Computer science, Health Policy, Public Health, Environmental and Occupational Health, medicine, Extrapolation, Overall survival, Cancer, medicine.disease, Projection (set theory), Algorithm, Term (time)
Published
2020

20. PRO50 THE ECONOMIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

Author

Crystal Watson, S. Duff, J. Worrall, R. Beckerman, and Arie Barlev

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Lymphoproliferative disorders, CHOP, medicine.disease, Chemotherapy regimen, Term (time), medicine, In patient, Adverse effect, business
Published
2019

21. PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION

Author

N. Boyer, Foluso Agboola, David Rind, N. Fluetsch, Brian Talon, Daniel R. Touchette, Varun M. Kumar, K. Fazioli, Bob G. Schultz, and S.J. Atlas

Subjects
medicine.medical_specialty, Esketamine, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, medicine.disease, Intensive care medicine, business, Treatment-resistant depression, Term (time), medicine.drug
Published
2019

24. PDB45 EVALUATING THE SHORT-TERM COST-UTILITY OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U100 IN BASAL-BOLUS REGIMENS FOR TYPE 2 DIABETES IN CHINA

Author

Luwen Shi, S. Han, L.Y. Zheng, H.K. Sun, and P.X. Dong

Subjects
Oncology, Insulin degludec, medicine.medical_specialty, Insulin glargine, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Basal bolus, Type 2 diabetes, medicine.disease, Term (time), Cost utility, Internal medicine, medicine, business, medicine.drug
Published
2019

25. PGI5 LONG TERM ECONOMIC VALUE OF TIGHT CONTROL WITH ADALIMUMAB-BASED TREATMENT IN CROHN'S DISEASE: THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Author

Luisa Arueira Chaves, RF dos Santos, R. Saad-Hossne, Roseli Peres Moreira, and W. J. Lee

Subjects
Crohn's disease, Actuarial science, business.industry, Health Policy, Perspective (graphical), Control (management), Public Health, Environmental and Occupational Health, medicine.disease, Public healthcare, Term (time), Value (economics), Adalimumab, Medicine, business, medicine.drug
Published
2019

26. PMH54 - PATTERNS OF LONG-TERM CUSTODIAL CARE IN PARKINSON DISEASE PSYCHOSIS

Author

K. Grady, Y. Peng, D.T. Gilbertson, M. Irfan, S. Li, H. Yan, J.B. Wetmore, and A. Shim

Subjects
Psychosis, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Custodial care, medicine, Disease, medicine.disease, business, Psychiatry, Term (time)
Published
2018

28. PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

Author

Monika Russel-Szymczyk, Barnaby Hunt, K. Rychna, J. Pöhlmann, and W. Parekh

Subjects
Czech, Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Basal insulin, Public Health, Environmental and Occupational Health, Cost-effectiveness analysis, Type 2 diabetes, medicine.disease, language.human_language, Term (time), language, Medicine, business
Published
2018

29. The Long-Term Social Value Of Better Targeting G-Csf Therapy To Cancer Patients At Risk Of Febrile Neutropenia

Author

Charles Bowers, Mina Kabiri, Alison Sexton Ward, E. van Eijndhoven, Dana P. Goldman, Alison R. Silverstein, Aylin Yucel, and Mark Bensink

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Cancer, medicine.disease, Term (time), Internal medicine, G-csf therapy, Medicine, business, Value (mathematics), Febrile neutropenia
Published
2018

30. PDB46 EVALUATING THE LONG-TERM COST-UTILITY OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U100 IN BASAL-BOLUS REGIMENS FOR TYPE 2 DIABETES IN CHINA

Author

Q.Y. Meng, S. Haikui, H. Shao, and X.C. Ma

Subjects
Insulin degludec, Oncology, medicine.medical_specialty, business.industry, Insulin glargine, Health Policy, Public Health, Environmental and Occupational Health, Basal bolus, Type 2 diabetes, medicine.disease, Term (time), Cost utility, Internal medicine, medicine, business, medicine.drug
Published
2019

31. PDB102 MODELLING PROGRESSION OF RISK FACTORS IN PATIENTS WITH TYPE 1 DIABETES: TOWARDS THE MOST APPROPRIATE FUNCTIONAL FORMS FOR A SIMULATION MODEL OF LONG-TERM HEALTH OUTCOMES

Author

Ann-Marie Svensson, Andrew J. Palmer, Josh Knight, Philip Clarke, Björn Eliasson, and An Tran-Duy

Subjects
Gerontology, Type 1 diabetes, Business economics, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, In patient, medicine.disease, business, Health outcomes, Term (time)
Published
2019

32. PCN306 REAL-WORLD STUDY OF HEALTHCARE UTILIZATION AND LONG-TERM PRODUCTIVITY LOSS IN CHRONIC GRAFT VERSUS HOST DISEASE IN SWEDEN

Author

Johan Liwing, T. Webb, N. Batyrbekova, F. Schain, J. Mattsson, and M. Remberger

Subjects
medicine.medical_specialty, Graft-versus-host disease, Healthcare utilization, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, Intensive care medicine, business, medicine.disease, Productivity, Term (time)
Published
2019

33. PRS11 HEALTHCARE COSTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND CONCURRENT LONG-TERM USE OF PRESCRIPTION OPIOIDS

Author

Matthew E. Borrego, Patricia Marshik, A.A. Kharat, Melissa H. Roberts, and Vishvas Garg

Subjects
COPD, medicine.medical_specialty, business.industry, Health Policy, Health care, Public Health, Environmental and Occupational Health, medicine, Pulmonary disease, Medical prescription, medicine.disease, business, Intensive care medicine, Term (time)
Published
2019

35. PND54 - A LONG TERM ANALYSIS OF THE CLINICAL AND COST EFFECTIVENESS OF GLATIRAMER ACETATE USING FINAL 10-YEAR RESULTS FROM THE UK MULTIPLE SCLEROSIS RISK SHARING SCHEME

Author

B. Rodgers-Gray, E Walters, S. Al-Izki, and DK Dhiraj

Subjects
medicine.medical_specialty, Cost effectiveness, business.industry, Health Policy, Multiple sclerosis, Public Health, Environmental and Occupational Health, medicine.disease, Term (time), medicine, Risk sharing, Glatiramer acetate, Intensive care medicine, business, medicine.drug
Published
2018

36. PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTING

Author

W. Parekh, Barnaby Hunt, Roberta Montagnoli, G. Lastoria, and J. Pöhlmann

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Basal insulin, Public Health, Environmental and Occupational Health, Cost-effectiveness analysis, Type 2 diabetes, medicine.disease, 030226 pharmacology & pharmacy, Term (time), 03 medical and health sciences, 0302 clinical medicine, Medicine, business, 030217 neurology & neurosurgery
Published
2018

37. PDB67 - ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON SUSTAIN 7

Author

Barnaby Hunt, Samuel J. P. Malkin, C. S. Hoxer, V. Martín, and D.G. Belbute

Subjects
Pediatrics, medicine.medical_specialty, business.industry, 030503 health policy & services, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Once weekly, Type 2 diabetes, Cost-effectiveness analysis, medicine.disease, Term (time), 03 medical and health sciences, 0302 clinical medicine, medicine, Dulaglutide, 030212 general & internal medicine, 0305 other medical science, business, medicine.drug
Published
2018

38. PDB53 - EVALUATING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL, INCIDENCE OF SEVERE HYPOGLYCEMIA, AND LONG-TERM HEALTH ECONOMIC OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED STATES

Author

R.F. Pollock and W.J. Valentine

Subjects
Type 1 diabetes, Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Incidence (epidemiology), Public Health, Environmental and Occupational Health, medicine.disease, Severe hypoglycemia, Term (time), Medicine, In patient, business, Glycemic
Published
2018

39. A Network Meta-Analysis (NMA) to Assess the Longer-Term Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin

Author

A. Schubert, M. Schroeder, Vanessa Taieb, AT Nielsen, M Pacou, and Cheryl Neslusan

Subjects
Canagliflozin, medicine.medical_specialty, Relative efficacy, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Type 2 diabetes, medicine.disease, Bioinformatics, Term (time), Metformin, Text mining, Meta-analysis, Internal medicine, medicine, In patient, business, medicine.drug
Published
2015
Full Text
View/download PDF

41. Can Qva149 Improve Short Term Outcomes In Patients With Copd Without Increasing The Overall Treatment Costs For The Portuguese Nhs? Optimizing Treatment Outcomes With A Responsible Use Of Limited Resources

Author

D. Viriato, J Carrasco, and I Cardoso

Subjects
COPD, medicine.medical_specialty, business.industry, Health Policy, Treatment outcome, Public Health, Environmental and Occupational Health, medicine.disease, Data science, language.human_language, Term (time), Text mining, language, Medicine, In patient, Portuguese, Treatment costs, business, Intensive care medicine, Limited resources
Published
2015
Full Text
View/download PDF

42. Short And Long-Term Economic Impact of Secondary Hyperparathyroidism Treatment in Chronic Kidney Disease in Carlos Andrade Marin Hospital (Ecuador)

Author

Marco Fornasini, L Manjarres, G Padilla, M Cabezas, Adelin Albert, and P Sanchez

Subjects
Gerontology, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Medicine, Secondary hyperparathyroidism, Economic impact analysis, business, Intensive care medicine, medicine.disease, Term (time), Kidney disease
Published
2015
Full Text
View/download PDF

43. The Short-Term Health and Economic Burden of Gestational Diabetes Mellitus in Italy

Author

Helen Banks, Patrick Detzel, Giovanni Fattore, Chiara Benedetto, Livia Dainelli, and Michela Meregaglia

Subjects
Gestational diabetes, Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, medicine.disease, business, Term (time)
Published
2016

44. Are treatment sequences, adverse events, long-term disease progression adequately considered in cost-effectiveness analyses of rheumatoid arthritis ?: A critical economic litterature review

Author

O Scemama, S Ghabri, and J Li

Subjects
medicine.medical_specialty, Cost effectiveness, business.industry, Health Policy, Disease progression, Public Health, Environmental and Occupational Health, Alternative medicine, medicine.disease, Term (time), Rheumatoid arthritis, medicine, Physical therapy, Intensive care medicine, business, Adverse effect
Published
2016

45. Group-Based Trajectory Analysis of Long-Term Proton Pump Inhibitor Use and Dementia Risk in the Elderly

Author

Sung-Hsi Huang, Liang Kung Chen, Fei-Yuan Hsiao, Li Ning Peng, and L Tseng

Subjects
medicine.medical_specialty, Group based, medicine.drug_class, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Proton-pump inhibitor, medicine.disease, Term (time), Physical medicine and rehabilitation, medicine, Dementia, Trajectory analysis, business
Published
2018

47. A Cost-Outcome Study: A Real-World Investigation of Long-Term Inpatient Hospital Utilisation and Costs for a Retrospective Cohort of Bariatric Surgery Patients in an Australian Public Hospital System Based on Australia’s Activity Based Funding Model

Author

Andrew J. Palmer, Alexandr Kuzminov, Martin Hensher, D Davies, Alison Venn, Amanda L. Neil, Julie A Campbell, Barry Hagan, Melissa J. Green, and I Jordan

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Retrospective cohort study, medicine.disease, Obesity, Outcome (game theory), Term (time), Activity based funding, Public hospital, Emergency medicine, medicine, Cost analysis, business
Published
2018

48. Long-Term Cost-Effectiveness of Valbenazine and Deutetrabenazine For Tardive Dyskinesia

Author

Surrey M. Walton, K Harrigan, Daniel A. Ollendorf, SP Huang, S.J. Atlas, Varun M. Kumar, Richard H. Chapman, Foluso Agboola, and Touchette

Subjects
medicine.medical_specialty, business.industry, Cost effectiveness, Deutetrabenazine, Health Policy, Public Health, Environmental and Occupational Health, Medicine, Valbenazine, business, Tardive dyskinesia, medicine.disease, Intensive care medicine, Term (time)
Published
2018

49. Real-World Analysis of Treatment Patterns and Long-Term Effectiveness Among Patients with Advanced Neuroendocrine Tumors of Lung Origin (Lung Net): A Multicenter Study

Author

J Shea, Todor Totev, EK Bergsland, Duh, Maureen P. Neary, Al B. Benson, B Cai, Arvind Dasari, Matthew H. Kulke, and Lynn Huynh

Subjects
Oncology, medicine.medical_specialty, Lung, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Neuroendocrine tumors, medicine.disease, Term (time), medicine.anatomical_structure, Multicenter study, Internal medicine, medicine, business
Published
2018

50. Long-Term Epidemiological Impact of Pertuzumab+Trastuzmab on Metastatic Breast Cancer Incidence in Canada

Author

Mellissa Williamson, K Gururaj, C Tournier, E Reydet, M Coombes, and A Tomar

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Incidence (epidemiology), Public Health, Environmental and Occupational Health, medicine.disease, Metastatic breast cancer, Term (time), Internal medicine, Epidemiology, medicine, Pertuzumab, business, medicine.drug
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results